Login Register Cart 0
Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

A Systematic Review and Meta-analysis on the Role of Statins in the Prevention of Mortality Following Pancreatic Cancer

Author(s): Khatereh Anbari, Mehdi Mohammadian Amiri, Saeid Heidari-Soureshjani, Catherine MT Sherwin and Karamali Kasiri*

Volume 23, Issue 19, 2023

Published on: 12 September, 2023

Page: [2073 - 2082] Pages: 10

DOI: 10.2174/1871520623666230824095226

Price: $65

Abstract

Background: Pancreatic cancer (PC) is a type of cancer with a high incidence and case-fatality rate.

Objective: This study aimed to evaluate the role of statins in preventing mortality following PC based on scientific evidence with systematic review and meta-analysis method.

Methods: This meta-analysis considered studies published from 1980 till the end of 2022 in ISI Web of Science, Scopus, PubMed, Cochrane, Science Direct, Google Scholar, and Embase databases. Funnel diagrams and Begg's and Egger's tests were used to assess the publication bias.

Results: In general, this meta-analysis has included 19 studies (13 cohort studies, 4 case-control, and 2 randomized clinical trials (RCTs)) and a total of 100,888 patients with PC. The risk of mortality of PC in statin users in total was 0.86 (95% CI: 0.80 - 0.92, P-value <0.001); in the case-control studies, it was equal to 0.53 (0.34-0.83); in the cohort studies, it was equal to 0.87 (0.82-0.92, P-value <0.001); in RCTs, it was equal to 1.19 (0.99-1.42, P-value <0.001); in studies with good quality score category, it was equal to 0.92 (0.86-0.99, P-value <0.001), and in articles of the moderate quality score category, it was equal to 0.73 (0.64-0.84, P-value <0.001). The results of statistical tests indicated the existence of publication bias (Begg's test (P-value = 0.002) and Egger's test (P-value = 0.004)).

Conclusion: Statins reduce the risk of mortality in patients with PC. However, no significant relation has been observed in RCTs. Therefore, it is necessary to be cautious in interpreting the results.

Next »
Graphical Abstract

[1]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
Rawla, P.; Sunkara, T.; Gaduputi, V. Epidemiology of pancreatic cancer: Global trends, etiology and risk factors. World J. Oncol., 2019, 10(1), 10-27.
[http://dx.doi.org/10.14740/wjon1166] [PMID: 30834048]
[3]
Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer Statistics, 2021. CA Cancer J. Clin., 2021, 71(1), 7-33.
[http://dx.doi.org/10.3322/caac.21654] [PMID: 33433946]
[4]
Cao, M.; Chen, W. Epidemiology of lung cancer in China. Thorac. Cancer, 2019, 10(1), 3-7.
[http://dx.doi.org/10.1111/1759-7714.12916] [PMID: 30485694]
[5]
Mizrahi, J.D.; Surana, R.; Valle, J.W.; Shroff, R.T. Pancreatic cancer. Lancet, 2020, 395(10242), 2008-2020.
[http://dx.doi.org/10.1016/S0140-6736(20)30974-0] [PMID: 32593337]
[6]
Longo, J.; van Leeuwen, J.E.; Elbaz, M.; Branchard, E.; Penn, L.Z. Statins as anticancer agents in the era of precision medicine. Clin. Cancer Res., 2020, 26(22), 5791-5800.
[http://dx.doi.org/10.1158/1078-0432.CCR-20-1967] [PMID: 32887721]
[7]
Barbalata, C.I.; Tefas, L.R.; Achim, M.; Tomuta, I.; Porfire, A.S. Statins in risk-reduction and treatment of cancer. World J. Clin. Oncol., 2020, 11(8), 573-588.
[http://dx.doi.org/10.5306/wjco.v11.i8.573] [PMID: 32879845]
[8]
Mangelinck, A.; Habel, N.; Mohr, A.; Gaspar, N.; Stefanovska, B.; Fromigué, O. Synergistic anti-tumor effect of simvastatin combined to chemotherapy in osteosarcoma. Cancers, 2021, 13(22), 5869.
[http://dx.doi.org/10.3390/cancers13225869] [PMID: 34831022]
[9]
Mohammadian-Hafshejani, A.; Sherwin, C.M.T.; Heidari-Soureshjani, S. Do statins play any role in reducing the incidence and mortality of ovarian cancer? A systematic review and meta-analysis. J. Prev. Med. Hyg., 2020, 61(3), E331-E339.
[PMID: 33150223]
[10]
Shi, M.; Zheng, H.; Nie, B.; Gong, W.; Cui, X. Statin use and risk of liver cancer: An update meta-analysis. BMJ Open, 2014, 4(9), e005399.
[http://dx.doi.org/10.1136/bmjopen-2014-005399] [PMID: 25227628]
[11]
Moon, D.C.; Lee, H.S.; Lee, Y.I.; Chung, M.J.; Park, J.Y.; Park, S.W.; Song, S.Y.; Chung, J.B.; Bang, S. Concomitant statin use has a favorable effect on gemcitabine-erlotinib combination chemotherapy for advanced pancreatic cancer. Yonsei Med. J., 2016, 57(5), 1124-1130.
[http://dx.doi.org/10.3349/ymj.2016.57.5.1124] [PMID: 27401642]
[12]
Wang, Q.; Zhi, Z.; Han, H.; Zhao, Q.; Wang, X.; Cao, S.; Zhao, J. Statin use improves the prognosis of ovarian cancer: An updated and comprehensive meta analysis. Oncol. Lett., 2022, 25(2), 65.
[http://dx.doi.org/10.3892/ol.2022.13648] [PMID: 36644149]
[13]
An, Y.; Sun, J.X.; Xu, M.Y.; Liu, C.Q.; Xu, J.Z.; Zhong, X.Y.; Hu, J.; Xia, Q.D.; Hu, H.L.; Wang, S.G. Statin use is associated with better prognosis of patients with prostate cancer after definite therapies: A systematic review and meta-analysis of cohort studies. J. Oncol., 2022, 2022, 1-10.
[http://dx.doi.org/10.1155/2022/9275466] [PMID: 36425939]
[14]
Li, Y.; He, X.; Ding, Y.; Chen, H.; Sun, L. Statin uses and mortality in colorectal cancer patients: An updated systematic review and meta‐analysis. Cancer Med., 2019, 8(6), 3305-3313.
[http://dx.doi.org/10.1002/cam4.2151] [PMID: 31069997]
[15]
Nakai, Y.; Isayama, H.; Sasaki, T.; Mizuno, S.; Sasahira, N.; Kogure, H.; Kawakubo, K.; Yamamoto, N.; Hirano, K.; Ijichi, H.; Tateishi, K.; Tada, M.; Koike, K. Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: Better prognosis with statin use in diabetic patients. Pancreas, 2013, 42(2), 202-208.
[http://dx.doi.org/10.1097/MPA.0b013e31825de678] [PMID: 23000889]
[16]
Jeon, C.Y.; Pandol, S.J.; Goodman, M.T. Survival time in pancreatic cancer patients with metabolic syndrome varies by use of insulin and statins. Cancer Res., 2014, 74(19_Supplement)(Suppl.), 2173-2173.
[http://dx.doi.org/10.1158/1538-7445.AM2014-2173]
[17]
Wu, B.U.; Chang, J.; Jeon, C.Y.; Pandol, S.J.; Huang, B.; Ngor, E.W.; Difronzo, A.L.; Cooper, R.M. Impact of statin use on survival in patients undergoing resection for early-stage pancreatic cancer. Am. J. Gastroenterol., 2015, 110(8), 1233-1239.
[http://dx.doi.org/10.1038/ajg.2015.217] [PMID: 26195180]
[18]
Lee, H.S.; Lee, S.H.; Lee, H.J.; Chung, M.J.; Park, J.Y.; Park, S.W.; Song, S.Y.; Bang, S. Statin use and its impact on survival in pancreatic cancer patients. Medicine, 2016, 95(19), e3607.
[http://dx.doi.org/10.1097/MD.0000000000003607] [PMID: 27175667]
[19]
Hong, J.Y.; Nam, E.M.; Lee, J.; Park, J.O.; Lee, S.C.; Song, S.Y.; Choi, S.H.; Heo, J.S.; Park, S.H.; Lim, H.Y.; Kang, W.K.; Park, Y.S. Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients. Cancer Chemother. Pharmacol., 2014, 73(1), 125-130.
[http://dx.doi.org/10.1007/s00280-013-2328-1] [PMID: 24162380]
[20]
Jeon, C.Y.; Pandol, S.J.; Wu, B.; Cook-Wiens, G.; Gottlieb, R.A.; Merz, N.B.; Goodman, M.T. The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: A SEER-medicare analysis. PLoS One, 2015, 10(4), e0121783.
[http://dx.doi.org/10.1371/journal.pone.0121783] [PMID: 25830309]
[21]
Tingle, S.J.; Moir, J.A.; White, S.A. Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. World J. Gastrointest. Pathophysiol., 2015, 6(4), 235-242.
[http://dx.doi.org/10.4291/wjgp.v6.i4.235] [PMID: 26600982]
[22]
e, J.Y.; Lu, S.E.; Lin, Y.; Graber, J.M.; Rotter, D.; Zhang, L.; Petersen, G.M.; Demissie, K.; Lu-Yao, G.; Tan, X.L. Differential and joint effects of metformin and statins on overall survival of elderly patients with pancreatic adenocarcinoma: A large population-based study. Cancer Epidemiol. Biomarkers Prev., 2017, 26(8), 1225-1232.
[http://dx.doi.org/10.1158/1055-9965.EPI-17-0227] [PMID: 28619830]
[23]
Haukka, J.; Niskanen, L.; Auvinen, A. Risk of cause‐specific death in individuals with cancer—modifying role diabetes, statins and metformin. Int. J. Cancer, 2017, 141(12), 2437-2449.
[http://dx.doi.org/10.1002/ijc.31016] [PMID: 28840596]
[24]
Huang, B.Z.; Chang, J.I.; Li, E.; Xiang, A.H.; Wu, B.U. Influence of statins and cholesterol on mortality among patients with pancreatic cancer. J. Natl. Cancer Inst., 2017, 109(5), djw275.
[http://dx.doi.org/10.1093/jnci/djw275] [PMID: 28040693]
[25]
Farooqi, M.A.M.; Malhotra, N.; Mukherjee, S.D.; Sanger, S.; Dhesy-Thind, S.K.; Ellis, P.; Leong, D.P. Statin therapy in the treatment of active cancer: A systematic review and meta-analysis of randomized controlled trials. PLoS One, 2018, 13(12), e0209486.
[http://dx.doi.org/10.1371/journal.pone.0209486] [PMID: 30571754]
[26]
Abdel-Rahman, O. Statin treatment and outcomes of metastatic pancreatic cancer: A pooled analysis of two phase III studies. Clin. Transl. Oncol., 2019, 21(6), 810-816.
[http://dx.doi.org/10.1007/s12094-018-1992-3] [PMID: 30465184]
[27]
Kjaergard, L.L.; Villumsen, J.; Gluud, C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann. Intern. Med., 2001, 135(11), 982-989.
[http://dx.doi.org/10.7326/0003-4819-135-11-200112040-00010] [PMID: 11730399]
[28]
Jadad, A.R.; Moore, R.A.; Carroll, D.; Jenkinson, C.; Reynolds, D.J.M.; Gavaghan, D.J.; McQuay, H.J. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control. Clin. Trials, 1996, 17(1), 1-12.
[http://dx.doi.org/10.1016/0197-2456(95)00134-4] [PMID: 8721797]
[29]
Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses; Ottawa Hospital Research Institute: Ottawa, 2011, pp. 1-12.
[30]
Kozak, M.M.; Anderson, E.M.; von Eyben, R.; Pai, J.S.; Poultsides, G.A.; Visser, B.C.; Norton, J.A.; Koong, A.C.; Chang, D.T. Statin and metformin use prolongs survival in patients with resectable pancreatic cancer. Pancreas, 2016, 45(1), 64-70.
[http://dx.doi.org/10.1097/MPA.0000000000000470] [PMID: 26474429]
[31]
Beg, M.S.; Gupta, A.; Sher, D.; Ali, S.; Khan, S.; Gao, A.; Stewart, T.; Ahn, C.; Berry, J.; Mortensen, E.M. Impact of concurrent medication use on pancreatic cancer survival-SEER-medicare analysis. Am. J. Clin. Oncol., 2018, 41(8), 766-771.
[http://dx.doi.org/10.1097/COC.0000000000000359] [PMID: 28079594]
[32]
Hamada, T.; Khalaf, N.; Yuan, C.; Morales-Oyarvide, V.; Babic, A.; Nowak, J.A.; Qian, Z.R.; Ng, K.; Rubinson, D.A.; Kraft, P. Prediagnosis use of statins associates with increased survival times of patients with pancreatic cancer. Clin. Gastroenterol. Hepatol., 2018, 16(8), 1300-1306.
[http://dx.doi.org/10.1016/j.cgh.2018.02.022]
[33]
Birmann, B.M.; Barnard, M.E.; Bertrand, K.A.; Bao, Y.; Crous-Bou, M.; Wolpin, B.M.; De Vivo, I.; Tworoger, S.S. Nurses’ Health Study contributions on the epidemiology of less common cancers: Endometrial, ovarian, pancreatic, and hematologic. Am. J. Public Health, 2016, 106(9), 1608-1615.
[http://dx.doi.org/10.2105/AJPH.2016.303337] [PMID: 27459458]
[34]
Giovannucci, E.; Ascherio, A.; Rimm, E.B.; Colditz, G.A.; Stampfer, M.J.; Willett, W.C. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann. Intern. Med., 1995, 122(5), 327-334.
[http://dx.doi.org/10.7326/0003-4819-122-5-199503010-00002] [PMID: 7847643]
[35]
Iarrobino, N.A.; Gill, B.; Bernard, M.E.; Mishra, M.V.; Champ, C.E. Targeting tumor metabolism with statins during treatment for advanced-stage pancreatic cancer. Am. J. Clin. Oncol., 2018, 41(11), 1125-1131.
[http://dx.doi.org/10.1097/COC.0000000000000433] [PMID: 29509593]
[36]
Madnick, D.; Handorf, E.; Ortiz, A.; Sorice, K.; Nagappan, L.; Moccia, M.; Cheema, K.; Vijayvergia, N.; Dotan, E.; Lynch, S.M. Investigating disparities: The effect of social environment on pancreatic cancer survival in metastatic patients. J. Gastrointest. Oncol., 2020, 11(4), 633-643.
[http://dx.doi.org/10.21037/jgo-20-39] [PMID: 32953147]
[37]
Støer, N.C.; Bouche, G.; Pantziarka, P.; Sloan, E.K.; Andreassen, B.K.; Botteri, E. Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: A nationwide registry-based study in Norway. Acta Oncol., 2021, 60(9), 1146-1153.
[http://dx.doi.org/10.1080/0284186X.2021.1953136] [PMID: 34338111]
[38]
Peltomaa, A.I.; Talala, K.; Taari, K.; Tammela, T.L.J.; Auvinen, A.; Murtola, T.J. Inverse association between statin use and cancer mortality relates to cholesterol level. Cancers, 2022, 14(12), 2920.
[http://dx.doi.org/10.3390/cancers14122920] [PMID: 35740586]
[39]
Tamburrino, D.; Crippa, S.; Partelli, S.; Archibugi, L.; Arcidiacono, P.G.; Falconi, M.; Capurso, G. Statin use improves survival in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Dig. Liver Dis., 2020, 52(4), 392-399.
[http://dx.doi.org/10.1016/j.dld.2020.01.008] [PMID: 32113888]
[40]
Jiang, W.; Hu, J.W.; He, X.R.; Jin, W.L.; He, X.Y. Statins: A repurposed drug to fight cancer. J. Exp. Clin. Cancer Res., 2021, 40(1), 241.
[http://dx.doi.org/10.1186/s13046-021-02041-2] [PMID: 34303383]
[41]
Jian-Yu, E.; Graber, J.M.; Lu, S.E.; Lin, Y.; Lu-Yao, G.; Tan, X.L. Effect of metformin and statin use on survival in pancreatic cancer patients: A systematic literature review and meta-analysis. Curr. Med. Chem., 2018, 25(22), 2595-2607.
[http://dx.doi.org/10.2174/0929867324666170412145232] [PMID: 28403788]
[42]
Wang, D.; Rodriguez, E.A.; Barkin, J.S.; Donath, E.M.; Pakravan, A.S. Statin use shows increased overall survival in patients diagnosed with pancreatic cancer. Pancreas, 2019, 48(4), e22-e23.
[http://dx.doi.org/10.1097/MPA.0000000000001276] [PMID: 30973465]
[43]
Tilija Pun, N.; Jeong, C.H. Statin as a potential chemotherapeutic agent: Current updates as a monotherapy, combination therapy, and treatment for anti-cancer drug resistance. Pharmaceuticals, 2021, 14(5), 470.
[http://dx.doi.org/10.3390/ph14050470] [PMID: 34065757]
[44]
Vallianou, N.; Kostantinou, A.; Kougias, M.; Kazazis, C. Statins and cancer. Anticancer. Agents Med. Chem., 2014, 14(5), 706-712.
[http://dx.doi.org/10.2174/1871520613666131129105035] [PMID: 24295174]
[45]
Joharatnam-Hogan, N.; Alexandre, L.; Yarmolinsky, J.; Lake, B.; Capps, N.; Martin, R.M.; Ring, A.; Cafferty, F.; Langley, R.E. Statins as potential chemoprevention or therapeutic agents in cancer: A model for evaluating repurposed drugs. Curr. Oncol. Rep., 2021, 23(3), 29.
[http://dx.doi.org/10.1007/s11912-021-01023-z] [PMID: 33582975]
[46]
Haj Hussein, B.; Kasabri, V.; Al-Hiari, Y.; Arabiyat, S.; Ikhmais, B.; Alalawi, S.; Al-Qirim, T. Selected statins as dual antiproliferative-antiinflammatory compounds. Asian Pac. J. Cancer Prev., 2022, 23(12), 4047-4062.
[http://dx.doi.org/10.31557/APJCP.2022.23.12.4047] [PMID: 36579985]
[47]
Zhang, Y.; Liang, M.; Sun, C.; Qu, G.; Shi, T.; Min, M.; Wu, Y.; Sun, Y. Statin use and risk of pancreatic cancer. Pancreas, 2019, 48(2), 142-150.
[http://dx.doi.org/10.1097/MPA.0000000000001226] [PMID: 30640225]
[48]
Mansouri, A.; Reiner, Ž.; Ruscica, M.; Tedeschi-Reiner, E.; Radbakhsh, S.; Bagheri Ekta, M.; Sahebkar, A. Antioxidant effects of statins by modulating Nrf2 and Nrf2/HO-1 signaling in different diseases. J. Clin. Med., 2022, 11(5), 1313.
[http://dx.doi.org/10.3390/jcm11051313] [PMID: 35268403]
[49]
Friesen, J.A.; Rodwell, V.W. The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases. Genome Biol., 2004, 5(11), 248.
[http://dx.doi.org/10.1186/gb-2004-5-11-248] [PMID: 15535874]
[50]
Fatehi Hassanabad, A. Current perspectives on statins as potential anti-cancer therapeutics: Clinical outcomes and underlying molecular mechanisms. Transl. Lung Cancer Res., 2019, 8(5), 692-699.
[http://dx.doi.org/10.21037/tlcr.2019.09.08] [PMID: 31737505]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy